Prospective Double blind Randomized controlled clinical study on Ayurvedic intervention (Sarpgandha Mishran) vs Amlodipine for the management of stage-I Primary Hypertension

Central Council for Research in Ayurvedic Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•1.Patients of either sex aged 30-65 years
•2.Diagnosed patients of stage-I essential hypertension as per 8th report of JNC (140-159 mm of Hg SBP and 90-99 mm of Hg DBP)
•3.Willing and able to participate for 3 months

•1.Patients who have history of Myocardial Infarction, congestive cardiac failure, Stroke or Arrhythmia in the last 6 months.
•2.Secondary hypertension.
•3.Patients with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.4 mg/dl),uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Neurological disorders, endocrine disorders, etc.) or known cases of malignancy.
•4.Known cases of uncontrolled Diabetes Mellitus.
•5.Women who are planning for conception / pregnant or lactating.
•6.Patients suffering from Psychosis/depressive illness.
•7.H/o hypersensitivity to any of the trial drugs or their ingredients.
•8.Patient taking participation in any other clinical trial.
•9.Participants who were tested COVID-19 positive (through a positive RT-PCR) in the last 30days.
•10.Participants with Post COVID-19 complications or BP fluctuations following disease.
•11.Participants who are still on COVID-19 related medical interventions.
•12.Any other condition, which the P.I. thinks, may jeopardize the safety of the patients.

发起方